Corrigendum to the Integrated Annual Report for the financial year 2025-26

Date: August 13, 2026 To, To, The Manager, The Manager Lis(cid:415)ng Department, Lis(cid:415)ng Department BSE Limited Na(cid:415)onal Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Plot no. C/1, Block Dalal Street – Fort Bandra Kurla Complex, Bandra (East), Mumbai 400001 Mumbai 400051 Scrip Code: 544578 N S E S y m b o l : R U B I C O N ISIN- INE506V01022 Sub: Corrigendum to the Integrated Annual Report for the financial year 2025-26 Dear Sir/Madam, This is with reference to our in(cid:415)ma(cid:415)on dated August 3, 2026, regarding the No(cid:415)ce of 27th Annual General Mee(cid:415)ng along with Integrated Annual Report of the Company for the financial year 2025-26. Please note the following minor correc(cid:415)ons made to the Annual Report to fix a few typographical errors: 1. Management Discussion & Analysis (Page nos. 76–78 of the Report): Corrected a few figures. 2. Other Minor Alignments: Adjusted the Shareholding Pa(cid:425)ern categories to match our filing for the quarter ended March 31, 2026 and updated the percentage stake acquired in Arinna Lifesciences Limited. All other contents of the Integrated Annual Report for FY 2025-26 remain unchanged. There are no changes to the No(cid:415)ce of 27th Annual General Mee(cid:415)ng. The revised Integrated Annual Report is a(cid:425)ached herewith and is also available on Company’s website at www.rubicon.co.in. Kindly take the above informa(cid:415)on on record. Thanking you, Yours faithfully, For Rubicon Research Limited (Formerly known as Rubicon Research Private Limited) Deepashree Tanksale Company Secretary and Compliance Officer M. No.: A28132 Encl.: As Above Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744 Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India (cid:44562)(cid:44563) +91-22-61414000 / 50414000 | (cid:44604)(cid:44605)(cid:44606)(cid:44607)(cid:44608) reachus@rubicon.co.in | (cid:33362) www.rubicon.co.in Rubicon Research Limited Integrated Annual Report 2025-26 Corporate Overview Healthcare is meaningful when it reaches people 04-69 with consistency, quality and care they can trust. As expectations evolve, the challenge lies in making 04 About Us therapies more effective, accessible and patient- Scan the QR code to know 06 FY 2025-26 at a Glance more about us centric, without compromising affordability or 07 Global Footprint or outcomes. This is where scientific innovation must 08 Message from our CEO Visit our website move beyond discovery to deliver real impact. www.rubicon.co.in 10 Our Journey 12 Our Manufacturing Capabilities Statutory Reports At Rubicon Research Limited, our journey Our approach is anchored in three defining 14 Our Research is shaped by a clear belief: innovation must principles: Innovation, Quality and Care. 70-160 and Development serve a purpose. As an IP-led specialty Innovation drives us to reimagine drug pharmaceutical company, we bring together delivery and improve better patient 15 Our Logistics and Distribution strong formulation expertise and proprietary outcomes. Quality ensures that every 70 Management drug delivery technologies to solve complex product meets the highest regulatory 16 Our Offerings Discussion and Analysis challenges and improve therapeutic and industry standards. Care remains 18 Our Blueprint for 80 Board’s Report effectiveness. From oral solids to injectables at the heart of everything we do, guiding Scalable Growth and advanced drug-device combinations, our efforts to make healthcare more 101 Business Responsibility our diverse portfolio demonstrates a accessible and meaningful for patients 22 Operating Environment and Sustainability Report Forward-looking statements commitment to addressing unmet medical around the world. 24 Value Creation Model 137 Corporate Some information in this report may needs across global markets. contain forward-looking statements which Governance Report include statements regarding Company’s 26 Stakeholder Engagement expected financial position and results of operations, business plans and prospects 30 Financial Capital etc. and are generally identified by forward-looking words such as “believe,” 34 Manufactured Capital “plan,” “anticipate,” “continue,” “estimate,” “expect,” “may,” “will” or other similar words. Forward-looking statements 42 Intellectual Capital Supported by a strong are dependent on assumptions or basis underlying such statements. We have 48 Human Capital Financial Statements global development chosen these assumptions or basis in good faith, and we believe that they are 58 Natural Capital 161-275 network and robust reasonable in all material respects. However, we caution that actual results, 62 Social and manufacturing performances or achievements could differ Relationship Capital materially from those expressed or implied capabilities, we continue to in such forward-looking statements. We 161 Standalone undertake no obligation to update or revise 66 Board of Directors translate scientific insight any forward-looking statement, whether Financial Statement as a result of new information, future 68 Company Information into real-world solutions. events, or otherwise. 219 Consolidated 69 Historic Financial Financial Statement As we look ahead, our Performance emphasis remains on advancing differentiated therapies, enabling better health outcomes and contributing to a future Contents where healthcare is effective, equitable and within reach for all. Innovation Innovation At Rubicon Research Limited (Rubicon Research), innovation transforms scientific expertise into meaningful healthcare solutions. Our Research & Development capabilities combine deep formulation knowledge with proprietary drug delivery technologies to address complex therapeutic challenges, while our manufacturing excellence ensures these innovations are produced with precision, quality and consistency at scale. This integration ensures that innovation is not confined to discovery, but carried through to delivery, translating into better efficacy, improved patient experience and reliable access. In doing so, science creates holistic value: for patients through better outcomes. Rubicon Research Limited Integrated Annual Report 2025-26 Corporate Overview Statutory Reports Financial Statements About Us Redefining Medicine, Acquisition Elevating Lives Impopharma Canada Limited Validus Pharmaceuticals LLC AimRx 3PL LLC We acquired Impopharma Canada We acquired Validus Pharmaceuticals We acquired AimRx 3PL LLC (AimRx), a Limited, bolstering our capabilities in LLC (Validus), a New Jersey-based US-based provider of logistics services nasal and pulmonary drug development. marketer of brand-name products. to pharmaceutical companies, with a We design and deliver innovative, patient-centric Keeping a strategic emphasis on The acquisition included a US FDA and Validus specialises in CNS and CVS warehouse in East Brunswick, New regulated markets, the United States pharmaceutical solutions that address unmet Health Canada-inspected facility in therapies, including products like Jersey. AimRx is licensed to distribute (US), in particular, we have positioned Concord, Toronto, now serving as our Equetro® and Lopressor®. This prescription pharmaceuticals across medical needs globally, thus improving people’s ourselves as a significant player in the drug-device combination development acquisition expands Rubicon Research’s 45 states. The acquisition expands lives. As an IP-led specialty pharmaceutical global pharmaceutical landscape. Our Center. This expansion reinforces branded specialty product pipeline and our distribution infrastructure in the diverse portfolio includes oral solids, our position in inhaler and nasal drug builds its presence in the US market, United States, supporting the growing company, we leverage proprietary drug delivery liquids, nasal, oph [Showing first 8,000 characters — download PDF for full document]